Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

Angelo Baldassare Cefalu', Maurizio Averna, Giovanni B. Vigna, Robert A. Hegele, Cesare R. Sirtori, Anna M. E. Du Plessi, Prediman K. Shah, Claudia Stefanutti, Hendrik Du Toit Theron, Hendrik Du Toit Theron, Daniel Gaudet, Cesare R. Sirtori, Cesare R. Sirtori, William J. Sasiela, Leanne T. Bloedon, Marina Cuchel, Emma A. Meagher, Dirk J. Blom, A. David Marais, Daniel J. RaderKathleen J. Propert, Davide Noto

Risultato della ricerca: Articlepeer review

460 Citazioni (Scopus)

Abstract

Patients with homozygous familial hypercholesterolaemia respond inadequately to existing drugs. We aimed to assess the efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in adults with this disease.
Lingua originaleEnglish
pagine (da-a)40-46
Numero di pagine7
RivistaThe Lancet
Volume381
Stato di pubblicazionePublished - 2013

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2700???

Fingerprint Entra nei temi di ricerca di 'Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study'. Insieme formano una fingerprint unica.

Cita questo